Total Payments
$1.7M
2024 Payments
$231,797
Companies
35
Transactions
2,240
Medicare Patients
665
Medicare Billing
$73,591
Payment Breakdown by Category
Other$1.3M (72.7%)
Consulting$264,226 (15.3%)
Travel$154,038 (8.9%)
Food & Beverage$53,703 (3.1%)
Research$121.01 (0.0%)
Education$27.17 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 330 | 59.4% |
| Consulting Fee | $264,226 | 97 | 15.3% |
| Travel and Lodging | $154,038 | 682 | 8.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $109,150 | 30 | 6.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $87,070 | 29 | 5.0% |
| Food and Beverage | $53,703 | 1,046 | 3.1% |
| Honoraria | $32,320 | 20 | 1.9% |
| Unspecified | $121.01 | 2 | 0.0% |
| Education | $27.17 | 4 | 0.0% |
Payments by Type
General
$1.7M
2,238 transactions
Research
$121.01
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $313,288 | 476 | $0 (2024) |
| Eisai Inc. | $271,335 | 277 | $0 (2024) |
| Gilead Sciences, Inc. | $228,230 | 401 | $0 (2024) |
| Exelixis Inc. | $172,035 | 194 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $146,970 | 228 | $0 (2020) |
| Intercept Pharmaceuticals, Inc. | $122,026 | 158 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $84,190 | 83 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $77,259 | 85 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $74,130 | 36 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42,096 | 62 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $231,797 | 253 | Ipsen Biopharmaceuticals, Inc ($74,130) |
| 2023 | $216,803 | 258 | Exelixis Inc. ($55,488) |
| 2022 | $177,533 | 228 | ABBVIE INC. ($35,016) |
| 2021 | $133,255 | 150 | Eisai Inc. ($38,501) |
| 2020 | $112,816 | 138 | Eisai Inc. ($24,560) |
| 2019 | $267,766 | 342 | AbbVie, Inc. ($73,377) |
| 2018 | $248,485 | 387 | AbbVie, Inc. ($81,889) |
| 2017 | $338,262 | 484 | Bayer HealthCare Pharmaceuticals Inc. ($110,018) |
All Payment Transactions
2,240 individual payment records from CMS Open Payments — Page 1 of 90
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $131.32 | General |
| 12/26/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | Cash or cash equivalent | $14.30 | General |
| 12/19/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,880.00 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,150.00 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $80.84 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $46.00 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $32.20 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $24.12 | General |
| Category: Oncology | ||||||
| 12/17/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: VIROLOGY | ||||||
| 12/16/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,115.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/11/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,580.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Exelixis Inc. | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $5,180.00 | General |
| 12/10/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,046.00 | General |
| Category: Rare Disease | ||||||
| 12/10/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $121.14 | General |
| Category: Rare Disease | ||||||
| 12/10/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: LIVER DISEASE | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.04 | General |
| 12/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $4.37 | General |
| 12/07/2024 | ABBVIE INC. | MAVYRET (Drug) | Travel and Lodging | In-kind items and services | $847.76 | General |
| Category: VIROLOGY | ||||||
| 12/07/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $70.00 | General |
| Category: VIROLOGY | ||||||
| 12/07/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: VIROLOGY | ||||||
| 12/07/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: VIROLOGY | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,296.00 | General |
| 12/06/2024 | ABBVIE INC. | MAVYRET (Drug) | Travel and Lodging | In-kind items and services | $184.87 | General |
| Category: VIROLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $118.58 | General |
| Category: VIROLOGY | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $73.21 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN9535-4321 | Novo Nordisk AS | $121.01 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 128 | 191 | $31,427 | $13,601 |
| 2022 | 5 | 159 | 225 | $50,056 | $16,371 |
| 2021 | 6 | 157 | 234 | $66,478 | $20,820 |
| 2020 | 9 | 221 | 298 | $75,448 | $22,799 |
Total Patients
665
Total Services
948
Medicare Billing
$73,591
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 28 | 82 | $17,548 | $7,559 | 43.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 30 | 32 | $5,056 | $2,070 | 40.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 22 | 24 | $3,792 | $1,833 | 48.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 13 | 16 | $2,528 | $1,207 | 47.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 17 | 18 | $1,800 | $775.80 | 43.1% |
| 91200 | Measurement of liver stiffness | Facility | 2023 | 18 | 19 | $703.00 | $155.99 | 22.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 77 | 101 | $15,958 | $7,229 | 45.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 27 | 69 | $14,766 | $5,508 | 37.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 13 | $5,122 | $2,009 | 39.2% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Office | 2022 | 16 | 16 | $13,248 | $1,435 | 10.8% |
| 91200 | Measurement of liver stiffness | Facility | 2022 | 26 | 26 | $962.00 | $190.06 | 19.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 33 | 92 | $19,688 | $7,559 | 38.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 64 | 82 | $12,956 | $6,238 | 48.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 17 | 17 | $6,698 | $2,567 | 38.3% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Office | 2021 | 12 | 12 | $14,124 | $2,419 | 17.1% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Office | 2021 | 15 | 15 | $12,420 | $1,896 | 15.3% |
| 91200 | Measuring the stiffness in the liver via elastography | Facility | 2021 | 16 | 16 | $592.00 | $141.44 | 23.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 39 | 108 | $23,112 | $8,988 | 38.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 18 | 18 | $7,092 | $2,936 | 41.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 33 | 36 | $4,833 | $2,156 | 44.6% |
| 45378 | Diagnostic examination of large bowel using an endoscope | Office | 2020 | 16 | 16 | $13,248 | $1,908 | 14.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Office | 2020 | 11 | 11 | $12,947 | $1,763 | 13.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 16 | 16 | $4,288 | $1,679 | 39.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 27 | 28 | $4,424 | $1,664 | 37.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 19 | 21 | $2,182 | $748.87 | 34.3% |
About Dr. Pierre Gholam, MD
Dr. Pierre Gholam, MD is a Gastroenterology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477579647.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Pierre Gholam, MD has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $231,797 received in 2024. These payments were reported across 2,240 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.0M).
As a Medicare-enrolled provider, Gholam has provided services to 665 Medicare beneficiaries, totaling 948 services with total Medicare billing of $73,591. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Cleveland, OH
- Active Since 07/14/2006
- Last Updated 01/15/2021
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1477579647
Products in Payments
- Lenvima (Drug) $271,314
- Epclusa (Drug) $163,076
- Mavyret (Drug) $162,464
- MAVYRET (Drug) $112,071
- OCALIVA (Drug) $103,643
- Stivarga (Drug) $100,827
- Cabometyx (Drug) $91,728
- CABOMETYX (Drug) $72,997
- IMFINZI (Biological) $70,885
- XIFAXAN (Drug) $70,091
- ZEPATIER (Drug) $63,909
- IQIRVO (Drug) $63,052
- Nexavar (Drug) $46,143
- Trulance (Drug) $30,692
- REZDIFFRA (Drug) $25,594
- Mulpleta (Drug) $25,359
- Viekira (Drug) $23,587
- OCA (Drug) $18,346
- Doptelet (Drug) $17,514
- Livdelzi (Drug) $15,681
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Cleveland
Ronnie Fass, Md, MD
Gastroenterology — Payments: $308,587
Gastroenterology $308,587
Dr. Taha Qazi, M.d, M.D
Gastroenterology — Payments: $185,665
Gastroenterology $185,665
Dr. Benjamin Cohen, Md, MD
Gastroenterology — Payments: $140,217
Gastroenterology $140,217
Amandeep Singh, Mbbs, MBBS
Gastroenterology — Payments: $111,838
Gastroenterology $111,838
Bo Shen, Md, MD
Gastroenterology — Payments: $103,946
Gastroenterology $103,946
Amitabh Chak, Md, MD
Gastroenterology — Payments: $90,197
Gastroenterology $90,197